Proactive Investors - Run By Investors For Investors

Imugene doses first patient in phase-two study of cancer vaccine

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong speaks to Proactive Investors about the pharma and biotech company’s HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.
The company recently dosed its first patient in the phase II study of the HER-Vaxx cancer vaccine.
The Phase 2 HER-Vaxx study is designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer overexpressing the HER-2 protein.
View full IMU profile View Profile

Imugene Ltd Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use